Bio-Path Holdings, Inc. (BPTH)
USD 0.15
(0.0%)
USD 0.15
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 3.22 Million USD | -79.84% |
| 2022 | 15.97 Million USD | -39.89% |
| 2021 | 26.56 Million USD | 61.26% |
| 2020 | 16.47 Million USD | -27.29% |
| 2019 | 22.66 Million USD | 870.45% |
| 2018 | 2.33 Million USD | -73.64% |
| 2017 | 8.85 Million USD | -27.37% |
| 2016 | 12.19 Million USD | 13.4% |
| 2015 | 10.75 Million USD | -30.51% |
| 2014 | 15.47 Million USD | 204.75% |
| 2013 | 5.07 Million USD | 116.7% |
| 2012 | 2.34 Million USD | -27.46% |
| 2011 | 3.23 Million USD | 3.94% |
| 2010 | 3.1 Million USD | -15.57% |
| 2009 | 3.68 Million USD | -16.08% |
| 2008 | 4.38 Million USD | 8829.45% |
| 2007 | 49.13 Thousand USD | -62.63% |
| 2006 | 131.49 Thousand USD | -7.52% |
| 2005 | 142.18 Thousand USD | -5.29% |
| 2004 | 150.12 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 5.11 Million USD | 189.48% |
| 2024 Q1 | 1.76 Million USD | -45.09% |
| 2023 Q4 | 3.22 Million USD | -35.87% |
| 2023 Q2 | 6.52 Million USD | -41.24% |
| 2023 FY | 3.22 Million USD | -79.84% |
| 2023 Q1 | 11.1 Million USD | -30.49% |
| 2023 Q3 | 5.02 Million USD | -23.04% |
| 2022 FY | 15.97 Million USD | -39.89% |
| 2022 Q3 | 18.53 Million USD | -11.76% |
| 2022 Q2 | 21 Million USD | -12.75% |
| 2022 Q1 | 24.07 Million USD | -9.37% |
| 2022 Q4 | 15.97 Million USD | -13.85% |
| 2021 Q2 | 31.12 Million USD | -5.96% |
| 2021 Q1 | 33.09 Million USD | 100.9% |
| 2021 FY | 26.56 Million USD | 61.26% |
| 2021 Q3 | 30.68 Million USD | -1.44% |
| 2021 Q4 | 26.56 Million USD | -13.4% |
| 2020 Q1 | 19.82 Million USD | -12.51% |
| 2020 Q2 | 17.52 Million USD | -11.63% |
| 2020 Q3 | 14.87 Million USD | -15.11% |
| 2020 Q4 | 16.47 Million USD | 10.77% |
| 2020 FY | 16.47 Million USD | -27.29% |
| 2019 Q1 | 21.31 Million USD | 813.02% |
| 2019 FY | 22.66 Million USD | 870.45% |
| 2019 Q4 | 22.66 Million USD | 28.79% |
| 2019 Q3 | 17.59 Million USD | -8.92% |
| 2019 Q2 | 19.31 Million USD | -9.38% |
| 2018 Q3 | 3.94 Million USD | -31.3% |
| 2018 Q2 | 5.74 Million USD | -20.29% |
| 2018 FY | 2.33 Million USD | -73.64% |
| 2018 Q1 | 7.2 Million USD | -18.67% |
| 2018 Q4 | 2.33 Million USD | -40.81% |
| 2017 Q2 | 9.43 Million USD | -6.73% |
| 2017 Q1 | 10.11 Million USD | -17.1% |
| 2017 FY | 8.85 Million USD | -27.37% |
| 2017 Q4 | 8.85 Million USD | 21.08% |
| 2017 Q3 | 7.31 Million USD | -22.43% |
| 2016 FY | 12.19 Million USD | 13.4% |
| 2016 Q4 | 12.19 Million USD | -9.27% |
| 2016 Q1 | 8.94 Million USD | -16.82% |
| 2016 Q3 | 13.44 Million USD | 88.26% |
| 2016 Q2 | 7.14 Million USD | -20.19% |
| 2015 Q2 | 13.29 Million USD | -6.71% |
| 2015 Q3 | 11.67 Million USD | -12.19% |
| 2015 Q4 | 10.75 Million USD | -7.86% |
| 2015 FY | 10.75 Million USD | -30.51% |
| 2015 Q1 | 14.24 Million USD | -7.94% |
| 2014 FY | 15.47 Million USD | 204.75% |
| 2014 Q4 | 15.47 Million USD | -4.95% |
| 2014 Q3 | 16.28 Million USD | -6.22% |
| 2014 Q2 | 17.36 Million USD | -6.63% |
| 2014 Q1 | 18.59 Million USD | 266.18% |
| 2013 Q3 | 5.75 Million USD | 53.57% |
| 2013 Q1 | 1.97 Million USD | -15.92% |
| 2013 Q2 | 3.74 Million USD | 90.02% |
| 2013 FY | 5.07 Million USD | 116.7% |
| 2013 Q4 | 5.07 Million USD | -11.68% |
| 2012 Q3 | 2.07 Million USD | -4.39% |
| 2012 Q1 | 2.7 Million USD | -16.18% |
| 2012 Q2 | 2.16 Million USD | -20.06% |
| 2012 Q4 | 2.34 Million USD | 13.22% |
| 2012 FY | 2.34 Million USD | -27.46% |
| 2011 Q2 | 3.66 Million USD | 12.34% |
| 2011 FY | 3.23 Million USD | 3.94% |
| 2011 Q4 | 3.23 Million USD | -5.09% |
| 2011 Q3 | 3.4 Million USD | -7.08% |
| 2011 Q1 | 3.26 Million USD | 4.92% |
| 2010 FY | 3.1 Million USD | -15.57% |
| 2010 Q1 | 3.6 Million USD | -2.1% |
| 2010 Q2 | 3.74 Million USD | 3.8% |
| 2010 Q3 | 3.2 Million USD | -14.26% |
| 2010 Q4 | 3.1 Million USD | -3.1% |
| 2009 Q3 | 3.35 Million USD | -6.88% |
| 2009 Q4 | 3.68 Million USD | 9.76% |
| 2009 Q2 | 3.6 Million USD | -6.99% |
| 2009 Q1 | 3.87 Million USD | -11.73% |
| 2009 FY | 3.68 Million USD | -16.08% |
| 2008 Q4 | 4.38 Million USD | -3.36% |
| 2008 FY | 4.38 Million USD | 8829.45% |
| 2008 Q1 | 5.01 Million USD | 8344.1% |
| 2008 Q2 | 4.76 Million USD | -5.02% |
| 2008 Q3 | 4.53 Million USD | -4.76% |
| 2007 FY | 49.13 Thousand USD | -62.63% |
| 2007 Q4 | 59.42 Thousand USD | 34.49% |
| 2007 Q2 | 49.13 Thousand USD | -30.2% |
| 2007 Q1 | 70.38 Thousand USD | -40.02% |
| 2007 Q3 | 44.18 Thousand USD | -10.06% |
| 2006 Q1 | 145.13 Thousand USD | 1.34% |
| 2006 Q3 | 117.02 Thousand USD | -11.0% |
| 2006 Q4 | 117.35 Thousand USD | 0.29% |
| 2006 FY | 131.49 Thousand USD | -7.52% |
| 2006 Q2 | 131.49 Thousand USD | -9.4% |
| 2005 Q2 | 142.18 Thousand USD | 0.0% |
| 2005 Q3 | 165.05 Thousand USD | 16.09% |
| 2005 Q4 | 143.2 Thousand USD | -13.24% |
| 2005 FY | 142.18 Thousand USD | -5.29% |
| 2004 FY | 150.12 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| America Great Health | 299.12 Thousand USD | -976.459% |
| Ampio Pharmaceuticals, Inc. | 5.73 Million USD | 43.863% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | 78.088% |
| Biora Therapeutics, Inc. | 31.21 Million USD | 89.684% |
| Better Therapeutics, Inc. | 22.94 Million USD | 85.965% |
| Calithera Biosciences, Inc. | 28.67 Million USD | 88.771% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | 13.606% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | 84.326% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | 84.756% |
| Evelo Biosciences, Inc. | 64.44 Million USD | 95.003% |
| Evolutionary Genomics, Inc. | 2.35 Million USD | -36.805% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | 95.465% |
| Galera Therapeutics, Inc. | 26.14 Million USD | 87.682% |
| Innovation1 Biotech Inc. | 75.99 Thousand USD | -4137.232% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | 73.539% |
| Molecular Templates, Inc. | 35.38 Million USD | 90.9% |
| Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | 26.343% |
| NexImmune, Inc. | 8.59 Million USD | 62.532% |
| Orgenesis Inc. | 14.55 Million USD | 77.872% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | 72.716% |
| Point of Care Nano-Technology, Inc. | 124.64 Thousand USD | -2483.378% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | 43.314% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -720.874% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 99.319% |
| Statera Biopharma, Inc. | 21.16 Million USD | 84.79% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | 68.135% |
| Trevena, Inc. | 40.6 Million USD | 92.07% |
| Vaxxinity, Inc. | 44.35 Million USD | 92.74% |
| Vaccinex, Inc. | 3.63 Million USD | 11.319% |
| Vicapsys Life Sciences, Inc. | 39.65 Thousand USD | -8019.831% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | 94.32% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -479.434% |